Managing hidradenitis suppurativa (HS) presents unique clinical nuances, especially when caring for pediatric patients and communities of color where HS disproportionately carries a high burden of morbidity and psychosocial impact.
While up to one-third of all HS patients experience symptom onset before age 18, managing younger patients remains a complex balancing act. Because long-term safety data for systemic therapies in children is limited, dermatologists often must rely on off-label extrapolations from adult literature.
A poster presented at Skin of Color Update shares:
- Presentation differences in children – and why early treatment matters
- First-line options for therapeutics, and when to consider hormonal and biologic therapies
- Safety considerations when prescribing systemics, including developmental risks and dosing dilemmas
Read the full interview with the poster’s lead author, Rachel Aronov of the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
